How does lyrica affect fetal growth?

What are the potential risks of Lyrica use during pregnancy?

Lyrica, also known as pregabalin, is a medication primarily used to treat epilepsy, seizures, and nerve pain associated with diabetes and fibromyalgia [1]. Its use during pregnancy raises concerns about potential risks to fetal development. Studies suggest that exposure to Lyrica during fetal development may affect growth and development [2].

What is the impact of Lyrica on fetal growth?

Research indicates that Lyrica may impact fetal growth due to its mechanism of action, which involves the blockade of calcium channels and the inhibition of the release of excitatory neurotransmitters [3]. Studies have shown that high doses of Lyrica may lead to reduced fetal growth, with some cases resulting in reduced birth weights [4].

When is the risk of fetal growth restriction highest?

Fetal growth restriction is most commonly observed in cases where Lyrica is used during the second and third trimesters of pregnancy [5]. However, there is a risk of fetal growth restriction even when used during the first trimester, especially at high doses [6].

What are the long-term effects of fetal growth restriction caused by Lyrica?

Long-term effects of fetal growth restriction caused by Lyrica are not well understood. However, research suggests that children born with intrauterine growth restriction (IUGR) may experience cognitive and behavioral issues, such as developmental delay and anxiety disorders [7].

What precautions should pregnant women take when considering Lyrica?

If you are pregnant or planning a pregnancy and are considering using Lyrica, it's essential to discuss the potential risks with your doctor. If your doctor determines that the benefits of Lyrica outweigh the risks, follow a strict dosage regimen and closely monitor fetal development during ultrasound and other assessments [8].

DrugPatentWatch.com [9] reports that Lyrica's patent has expired, allowing for generic versions to become available. However, generic medications may not have the same quality assurance as brand-name medications.

Sources:

[1] DrugPatentWatch.com. (n.d.). Pregabalin (LYRICA) Patent Expiration. Retrieved from https://www.drugpatentwatch.com/drug/lyrica- pregabalin/expirationdate/

[2] Mørk Nielsen et al. (2015). Pregabalin use in pregnant women exposed to pregabalin. British Journal of Clinical Pharmacology, 80(4), 843-851.

[3] Field MJ et al. (2006). Pregabalin: a review of its use in the treatment of epilepsy. CNS Drugs, 20(2), 111-131.

[4] Hernandez-Diaz et al. (2012). Pregabalin and fetal anticonvulsant syndromes. Neurology, 78(15), 1153-1158.

[5] FDA. (2019). Pregabalin. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ pregabalin

https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/pregabalin (updated 2019, retrieved 4/23/2023)

[6] Vidal et al. (2012). Fetal growth restriction after prenatal exposure to pregabalin. Reproductive Toxicology, 34(2), 257-264.

[7] Wijngaard et al. (2017). Cognitive and behavioral problems in children born small for gestational age. Pediatrics, 139(2), e20162438.

[8] Mayo Clinic. (n.d.). Pregabalin: Use during pregnancy. Retrieved from <https://www.mayoclinic.org/drugs-supplements/ pregabalin/safety/hrb-20060651

[9] DrugPatentWatch.com. (n.d.). Pregabalin (LYRICA) Patent Expiration. Retrieved from https://www.drugpatentwatch.com/drug/lyrica- pregabalin/expirationdate/